View Future GrowthBioqual 과거 순이익 실적과거 기준 점검 0/6Bioqual 의 수입은 연평균 -63.2%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 3.8%의 비율로 감소했습니다. 매출은 연평균 5.8%의 비율로 감소해 왔습니다.핵심 정보-63.21%순이익 성장률-63.22%주당순이익(EPS) 성장률Life Sciences 산업 성장률21.51%매출 성장률-5.80%자기자본이익률-3.53%순이익률-2.92%최근 순이익 업데이트28 Feb 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.공시 • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.공시 • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.공시 • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.공시 • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.공시 • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.공시 • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.공시 • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.공시 • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020.매출 및 비용 세부 내역Bioqual가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BIOQ 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비28 Feb 2642-110030 Nov 2547011031 Aug 2547-111031 May 2549-111028 Feb 2549-211030 Nov 2450-312031 Aug 2455-112031 May 2459012029 Feb 2463112030 Nov 2362012031 Aug 2362012031 May 2363112028 Feb 2365311030 Nov 2268511031 Aug 2266510031 May 2266510028 Feb 2264510030 Nov 2160610031 Aug 2158610031 May 215869028 Feb 215559030 Nov 205458031 Aug 205158031 May 204648029 Feb 204447030 Nov 194347031 Aug 194047031 May 193937028 Feb 193834030 Nov 183634031 Aug 183744031 May 183643028 Feb 183533030 Nov 173633031 Aug 173643031 May 173743028 Feb 173743030 Nov 163743031 Aug 163643031 May 163333029 Feb 163123030 Nov 152923031 Aug 152923031 May 1529230양질의 수익: BIOQ 은(는) 현재 수익성이 없습니다.이익 마진 증가: BIOQ는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIOQ은 수익성이 없으며 지난 5년 동안 손실이 연평균 63.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BIOQ의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BIOQ은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(3.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BIOQ는 현재 수익성이 없으므로 자본 수익률이 음수(-3.53%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 09:06종가2026/05/21 00:00수익2026/02/28연간 수익2025/05/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioqual, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 01+ 1 more updateBioqual, Inc. Announces Executive ChangesBIOQUAL, Inc. announces Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. Hanne Andersen Elyard received her PhD in microbiology from the Louisiana State University Health Sciences Center in 2000. She was a postdoctoral fellow in the AIDS Vaccine Program, SAIC-Frederick, Inc. from 2001 until 2005. In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, promoted to Vice President of Science in 2018 and subsequently she was promoted to Chief Scientific Officer in 2022. She has authored or co-authored more than 105 peer-reviewed scientific publications.
공시 • Apr 25BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices.
공시 • Jan 15BIOQUAL, Inc. Announces Changes to Board of DirectorsBIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022.
공시 • Oct 01Bioqual, Inc. Declares Dividend, Payable on October 28, 2024Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024.
공시 • Sep 15Bioqual, Inc. Announces Reduction in WorkforceBIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future.
공시 • Oct 06Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial OfficerBIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team.
공시 • Sep 28BIOQUAL Declares Dividend, Payable on October 27, 2022BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022.
공시 • May 10+ 2 more updatesBIOQUAL, Inc. Announces Retirement of Dave Newcomer as Chief Financial Officer, Effective June 3, 2022BIOQUAL, Inc. announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022. Newcomer will remain in his current position until then to support with the transition of his responsibilities to his successor. Newcomer’s position will be filled by Charles (Chris) C. Kirk, Jr., CPA. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both government contracting and services oriented companies as well as in the public accounting sector. Kirk has served as Director of Finance and Accounting for BIOQUAL over the past year.
공시 • Sep 22Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine CandidateBioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020.